# US 2014/0287066 A1 · Dosing regimens and methods of treatment using carbon monoxide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0287066 A1
- Document ID: US20140287066A1
- Status: Published application
- Kind: A1
- Application number: 14/299,772
- Filed: 2014-06-09
- Published: 2014-09-25
- Earliest claimed: 2010-05-14
- Assignees: Ikaria, Inc.
- Inventors: Helen H. Usansky; Khurram Jamil
- Web page: https://patentgrep.com/patent/US20140287066A1

## CPC

- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/007: {Pulmonary tract; Aromatherapy}
- Y10T 436/205831: Carbon monoxide only
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.

## Claims

### Claim 1

A method for treating a patient in need thereof with carbon monoxide, comprising administering to the patient an effective amount of carbon monoxide that results in a carboxyhemoglobin concentration of at least 3%.

### Claim 2 (depends on 1)

The method of claim 1, wherein the carboxyhemoglobin concentration is between about 3% and about 15%.

### Claim 3 (depends on 2)

The method of claim 2, wherein the carboxyhemoglobin concentration is between about 7% and about 15%.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient is administered carbon monoxide at a dose ranging between about 2 mg/kg to about 3 mg/kg for a sufficient time period that results in an effective carboxyhemoglobin concentration.

### Claim 5 (depends on 1)

The method of claim 1, wherein the patient is administered carbon monoxide at a dose of 3 mg/kg for a sufficient time period that results in an effective carboxyhemoglobin concentration.

### Claim 6 (depends on 1)

The method of claim 1, wherein carbon monoxide is administered to the patient in a gaseous form, a liquid form, or a combination thereof.

### Claim 7 (depends on 1)

The method of claim 1, further comprising administering an additional agent that has a therapeutic effect.

### Claim 8

A method for enhancing organ function following transplant thereof, comprising administering to a patient in need thereof an effective amount of carbon monoxide that results in a carboxyhemoglobin concentration of at least 3%, wherein carbon monoxide is administered intra-operatively during transplant of an organ.

### Claim 9 (depends on 8)

The method of claim 8, wherein the patient is administered carbon monoxide at the time of reperfusion.

### Claim 10 (depends on 8)

The method of claim 8, wherein the carboxyhemoglobin concentration is between about 7% and about 15%.

### Claim 11 (depends on 8)

The method of claim 8, wherein the organ is selected from kidney, liver, heart, skin, large or small intestine and pancreas.

### Claim 12 (depends on 8)

The method of claim 8, wherein the organ is kidney.

### Claim 13 (depends on 12)

The method of claim 12, wherein kidney function is improved as indicated by an improvement in at least one of: serum creatinine level or glomerular filtration rate.

### Claim 14 (depends on 8)

The method of claim 8, wherein said patient does not show any neurocognitive impairment when compared to placebo in the 24 hour period following treatment with carbon monoxide.

### Claim 15 (depends on 8)

The method of claim 8, wherein said patient does not show any neurocognitive impairment when compared to placebo in the time period up to 24 weeks following treatment with carbon monoxide.

### Claim 16 (depends on 8)

The method of claim 8, wherein said patient does not show any cardiovascular effects when compared to placebo during treatment with carbon monoxide.

### Claim 17 (depends on 8)

The method of claim 8, wherein said patient does not show any cardiovascular effects when compared to placebo in the 8 hour period following treatment with carbon monoxide.